trend
antivir
strategi
abbrevi
aid
acquir
immunodefici
syndrom
apolipoprotein
b
mrna
edit
complex
azac
daa
directact
antivir
denv
dengu
viru
ebv
ebola
viru
fmdv
footandmouth
diseas
viru
gbvb
gb
viru
b
fu
futp
gtp
triphosph
haart
highli
activ
antiretrovir
therapi
gener
procedur
effect
prevent
control
viral
infect
least
base
strategi
develop
last
centuri
half
vaccin
immunotherapi
chemotherapi
combin
one
main
reason
pathogen
viru
control
uniqu
featur
complex
multifacet
interact
host
cell
virus
also
cellular
pathogen
bacteria
fungi
protozoa
ampli
recogn
current
practic
prevent
treatment
clear
limit
one
difficulti
aris
potenti
variat
evolut
viral
cellular
pathogen
jeopard
control
strategi
mani
decad
limit
awar
adapt
potenti
pathogen
prevent
therapeut
design
implement
ignor
evolut
differ
expert
express
need
search
new
paradigm
approach
infecti
diseas
incorpor
darwinian
principl
togeth
concept
evolutionari
ecolog
consid
also
reimplement
old
method
passiv
antibodi
therapi
casadeval
stearn
william
casadeval
pirofski
recent
adapt
potenti
pathogen
particular
viral
quasispeci
dynam
conceptu
extens
pathogen
entiti
chapter
consid
aspect
diseas
control
problem
challeng
confront
symbol
portray
fig
use
one
way
depict
viral
quasispeci
throughout
book
line
repres
genom
symbol
line
repres
mutat
million
sheet
similar
one
shown
figur
necessari
repres
hepat
c
viru
hcv
genom
found
acut
infect
human
liver
given
time
point
precis
number
type
distribut
mutat
among
genom
vari
among
patient
also
function
time
patient
minut
later
slightli
differ
imag
produc
rel
proport
differ
genom
mutat
pattern
modifi
statement
infer
replic
mutat
paramet
determin
experiment
system
comparison
genom
composit
shorttim
interv
second
minut
hour
need
defin
extent
shortterm
variat
dynam
mutant
cloud
drawn
basi
estim
hcv
popul
number
probabl
underrepresent
number
mutat
per
genom
equal
applic
major
rna
virus
errorpron
dna
virus
quit
obviou
reader
previou
chapter
nonzero
probabl
mutat
present
mutant
spectrum
may
contribut
drug
resist
immun
evas
fit
enhanc
even
hidden
tini
minor
readi
select
challeng
clear
figur
scheme
quasispeci
intend
stress
challeng
control
replic
immens
divers
entiti
horizont
line
repres
viral
genom
symbol
line
symbol
mutat
typic
depict
quasispeci
use
throughout
book
discontinu
line
repres
genom
five
six
mutat
consid
exampl
suffici
number
sever
decreas
fit
fate
attain
verylowfrequ
level
elimin
evolv
popul
million
display
similar
one
shown
page
need
depict
hepat
c
viral
genom
present
individu
acut
infect
viru
trend
antivir
strategi
potenti
deleteri
mutat
load
excess
number
mutat
genom
symbol
fig
genom
drawn
discontinu
line
contain
five
mutat
assum
suffici
larg
number
decreas
fit
correspondingli
frequenc
potenti
descend
subsequ
replic
round
five
mutat
maintain
quasispeci
dynam
impos
howev
genom
move
highfrequ
lowfrequ
level
replac
newli
aris
mutant
display
higher
fit
mutant
cloud
highli
dynam
newli
aris
genom
incessantli
expos
scrutini
select
lotteri
random
drift
imag
portray
mutat
even
complex
add
recombin
genom
segment
reassort
case
virus
segment
multipartit
genom
chapter
point
view
antivir
intervent
virus
true
move
target
sens
repertoir
variant
inhibit
onetim
point
exactli
inhibit
subsequ
time
point
differ
may
irrelev
regard
efficaci
antivir
treatment
may
impact
dynam
chang
anticip
sinc
mutat
compromis
antivir
efficaci
aris
unpredict
way
appli
clinic
practic
mean
specif
inhibitor
combin
may
effect
mani
infect
individu
long
time
individu
short
time
rang
possibl
intermedi
outcom
new
antivir
strategi
discuss
chapter
take
consider
move
target
featur
virus
control
propos
increas
number
expert
awar
quasispeci
challeng
basic
statist
consider
justifi
need
use
multiepitop
vaccin
protect
variabl
virus
character
quasispeci
behavior
keep
mind
fig
discuss
section
chapter
present
chapter
focu
pharmacolog
approach
base
administr
antivir
inhibitor
immunotherapi
mention
potenti
ingredi
combin
therapi
antivir
inhibitor
systemat
select
drug
multidrug
resist
mutant
viral
popul
encourag
design
antivir
strategi
intend
avoid
viral
breakthrough
treatment
failur
main
option
clinic
practic
investig
use
nonmutagen
mutagen
antivir
inhibitor
summar
box
none
list
strategi
total
free
problem
select
drugresist
mutant
propos
intend
avoid
delay
select
next
discuss
major
featur
six
suggest
list
box
studi
advantag
combin
administr
two
drug
pioneer
hj
egger
tamm
part
studi
picornavirus
egger
tamm
egger
combin
therapi
appli
human
immunodefici
viru
type
great
success
control
acquir
immunodefici
syndrom
aid
drastic
reduc
aidsrel
mortal
type
treatment
term
highli
activ
antiretrovir
therapi
haart
implement
three
sometim
practic
propos
strategi
confront
move
target
challeng
antivir
inhibitor
two
differ
antiretrovir
agent
haart
efficaci
steadili
improv
due
avail
new
inhibitor
direct
differ
target
applic
rescu
treatment
gandhi
et
al
success
partial
due
side
effect
may
deriv
offtarget
activ
drug
incomplet
patient
adher
treatment
select
multidrugresist
viral
variant
retrovir
natur
render
viru
extinct
organ
difficult
endeavor
retrovirus
hepadnavirus
viral
dna
hidden
antivir
drug
serv
archiv
genom
whose
replic
reactiv
upon
treatment
discontinu
combin
therapi
could
coupl
effici
elimin
provir
reservoir
host
dna
de
crigni
mahmoudi
sadowski
hashemi
could
probabl
elimin
infect
organ
achiev
case
hcv
infect
mani
patient
treat
directact
antivir
agent
daa
gener
advantag
combin
therapi
monotherapi
larg
consequ
quasispeci
dynam
ampli
evidenc
clinic
practic
support
straightforward
statist
consider
theoret
model
viru
dynam
domingo
domingo
holland
ho
bonhoeff
et
al
pol
et
al
ribeiro
bonhoeff
le
mo
et
al
van
vaerenbergh
et
al
domingo
et
al
uller
bonhoeff
nijhui
et
al
see
also
section
chapter
furthermor
use
combin
therapi
conform
hit
earli
hit
hard
dictum
p
ehrlich
dd
ho
explain
section
chapter
misconcept
among
expert
mainli
among
politician
patient
advanc
phase
viral
infect
ie
precirrhot
cirrhot
patient
infect
hcv
treat
aggress
drug
combin
evolutionari
virolog
teach
us
patient
treat
strongli
possibl
earli
possibl
provid
side
effect
control
virus
given
chanc
walk
sequenc
space
search
adapt
pathway
chapter
adequ
combin
treatment
fulfil
purpos
second
propos
strategi
divid
antivir
treatment
two
step
first
induct
box
e
n
v
r
l
r
e
g
e
c
n
r
l
v
r
l
q
u
p
e
c
e
base
nonmutagen
inhibitor
combin
treatment
use
two
inhibitor
direct
independ
viral
target
split
treatment
induct
differ
mainten
regimen
target
cellular
function
use
drug
stimul
host
innat
immun
system
combin
use
immunotherapi
chemotherapi
lethal
mutagenesi
two
mode
sequenti
combin
administr
inhibitor
mutagen
mainten
step
von
kleist
et
al
base
theoret
model
develop
confront
infect
key
argument
treatment
chang
due
viru
rebound
mutant
resist
ineffect
drug
opportun
replic
patient
increas
viral
load
suppli
provir
archiv
inhibitorresist
latent
virus
thu
exclud
drug
compon
futur
combin
treatment
induct
regimen
follow
mainten
regimen
point
time
second
drug
find
low
viral
load
limit
number
mutant
resist
initi
treatment
critic
issu
implement
propos
time
treatment
switch
decreas
viral
load
result
induct
regimen
genet
phenotyp
barrier
mainten
regimen
clinic
trial
need
explor
interest
propos
potenti
broad
applic
mani
cellular
function
need
complet
step
viru
replic
cycl
good
deal
research
virolog
main
object
identifi
character
cellular
function
particip
viru
entri
cell
intracellular
multipl
releas
cell
immun
respons
sinc
cellular
protein
vari
respons
presenc
inhibitor
least
common
cell
type
within
time
frame
viral
infect
obviou
thought
administ
inhibitor
cellular
function
often
protein
need
sustain
viral
replic
inhibitor
suppress
viral
replic
without
select
inhibitorresist
mutant
geller
et
al
hopkin
et
al
garbelli
et
al
kumar
et
al
vidalain
et
al
hover
et
al
de
wild
et
al
ong
et
al
despit
potenti
benefit
two
major
problem
may
encount
antivir
agent
direct
cellular
protein
toxic
effect
deriv
suppress
alter
cellular
activ
target
protein
involv
ii
select
viral
mutant
insensit
presenc
inhibitor
despit
inhibitor
direct
viral
compon
insensit
may
come
least
three
differ
mechan
cellular
protein
target
inhibitor
form
complex
viral
protein
cours
viral
replic
amino
acid
substitut
viral
protein
may
permit
progress
infect
presenc
inhibitor
case
hcv
resist
nonimmunosuppress
cyclophilin
inhibitor
interact
cyclophilin
amino
acid
substitut
decreas
sensit
viru
although
precis
molecular
mechan
resist
debat
chatterji
et
al
sarrazin
zeuzem
delang
et
al
kwong
et
al
vermehren
sarrazin
develop
resist
may
host
celldepend
document
polioviru
resist
brefeldin
drug
target
cellular
guanin
nucleotid
exchang
factor
found
replic
complex
resist
mutant
select
hela
cell
vero
cell
degre
resist
polioviru
mutant
differ
among
cell
human
origin
resist
inflict
fit
cost
upon
viru
viktorova
et
al
inhibitor
target
cellular
receptor
viru
mutant
may
select
enter
cell
altern
receptor
document
use
coreceptor
dualtrop
virus
modifi
rant
regul
activ
normal
cell
express
secret
also
term
chemokin
cec
motif
ligand
select
coreceptor
switch
variant
scid
sever
combin
immunodefici
mous
model
mosier
et
al
mutant
amino
acid
substitut
loop
practic
propos
strategi
confront
move
target
challeng
antivir
inhibitor
env
protein
select
use
rather
coreceptor
see
also
section
chapter
loop
mutant
associ
maraviroc
resist
may
exhibit
increas
replic
capac
garciaperez
et
al
altern
mechan
overcom
inhibit
cellular
protein
viral
mutant
select
util
cellular
protein
complex
inhibitor
case
mutant
resist
small
coreceptor
inhibitor
mutant
amino
acid
substitut
loop
region
elsewher
env
use
either
free
inhibitorbound
enter
cell
effici
depend
express
level
host
cell
type
pugach
et
al
pugach
et
al
exampl
illustr
multipl
pathway
virus
exploit
overcom
inhibitor
direct
cellular
protein
constitut
addit
evid
abund
sourc
genet
variat
exist
virus
learn
new
trick
emphas
j
lederberg
connect
viral
diseas
emerg
reemerg
also
quot
section
chapter
sinc
mani
virus
use
altern
receptor
entri
cell
section
chapter
inhibitor
direct
viral
receptor
may
promot
select
viru
subpopul
use
differ
receptor
use
drug
stimul
host
innat
immun
system
inhibitor
enzym
de
novo
pyrimidin
biosynthesi
pathway
bequinar
stimul
innat
immun
respons
behav
broadspectrum
antivir
inhibitor
lucashourani
et
al
munierlehmann
et
al
vidalain
et
al
observ
effect
one
among
connect
establish
nucleotid
dna
metabol
immun
stimul
motani
et
al
pyrimidin
biosynthesi
inhibitor
addit
mechan
antivir
activ
might
involv
inhibit
lymphocyt
choriomening
viru
lcmv
replic
transcript
ortizriano
et
al
stimul
innat
immun
respons
may
restrict
select
escap
mutant
viru
must
mutat
sever
site
overcom
differ
branch
respons
case
interferon
ifn
resist
peral
et
al
multifactori
antivir
respons
increas
genet
phenotyp
barrier
resist
section
chapter
extens
advantag
combin
therapi
decreas
select
antiviralresist
mutant
consist
combin
use
immunotherapi
administr
neutral
antibodi
mean
immun
stimul
vaccin
togeth
antivir
inhibitor
concept
pioneer
rg
webster
colleagu
propos
strategi
control
influenza
virus
webster
et
al
author
show
simultan
administr
inactiv
vaccin
inhibitor
amantadin
confer
protect
influenza
viru
chicken
webster
et
al
relat
notion
investig
virus
differ
compon
immun
respons
seiler
et
al
li
et
al
howev
addit
model
vivo
experi
anim
clinic
trial
patient
necessari
investig
effect
combin
immunotherapeut
approach
line
relat
research
cancer
therapi
dalgleish
gener
outlook
strategi
summar
previou
section
potenti
combin
two
even
propos
list
box
encourag
provid
offtarget
effect
drug
immun
intervent
trend
antivir
strategi
control
side
effect
minim
trend
toward
complex
treatment
protocol
expect
respons
adapt
capac
viral
quasispeci
introduct
mutagen
agent
antivir
design
import
departur
exploit
one
corollari
quasispeci
behavior
error
threshold
relationship
introduc
section
chapter
basi
lethal
mutagenesi
discuss
next
lethal
mutagenesi
defin
process
viral
extinct
due
excess
mutat
viral
genom
jj
holland
colleagu
pioneer
studi
advers
effect
sever
chemic
mutagen
yield
infecti
polioviru
pv
vesicular
stomat
viru
vsv
cell
cultur
holland
et
al
term
lethal
mutagenesi
first
propos
l
loeb
ji
mullin
colleagu
studi
loss
replic
potenti
upon
multipl
human
cem
cell
presenc
deoxynucleosid
analog
loeb
et
al
experiment
design
lethal
mutagenesi
inspir
error
threshold
relationship
deriv
basic
equat
quasispeci
dynam
eigen
schuster
swetina
schuster
nowak
schuster
schuster
initi
elabor
simpl
singl
peak
fit
landscap
quasispeci
theori
one
main
corollari
stabil
genet
inform
replic
process
depend
two
paramet
error
rate
replic
amount
genet
inform
maintain
basic
equat
describ
relationship
maximum
toler
mutat
rate
max
ensur
transfer
genet
inform
next
gener
genom
length
n
includ
fig
relev
applic
error
threshold
concept
virolog
eigen
schuster
equat
import
variabl
superior
master
sequenc
surround
mutant
spectrum
denot
consist
numer
equat
virologist
intuit
understand
high
superior
domin
sequenc
reinforc
stabil
posit
popul
domin
master
sequenc
togeth
surround
mutant
cloud
environ
absenc
extern
perturb
larger
mutat
input
necessari
destabil
distribut
drive
mutant
spectrum
toward
extinct
addit
factor
modifi
stabil
mutant
distribut
posit
error
threshold
mathemat
justif
practic
implic
virolog
detail
schuster
particular
relev
viru
popul
stabil
influenc
fit
landscap
mainten
genet
inform
first
noteworthi
result
theoret
studi
error
threshold
present
realist
rug
fit
landscap
propos
best
describ
virus
basi
experiment
evid
see
also
section
chapter
second
posit
error
threshold
move
toward
lower
mutat
rate
rugged
fit
landscap
repres
paramet
consist
band
fit
valu
increas
replic
virus
variabl
fit
landscap
eg
variabl
environment
condit
versu
constant
environ
may
affect
eas
extinct
increas
mutagenesi
larg
unexplor
question
sever
theoret
model
present
explain
lethal
mutagenesi
virus
review
tejero
et
al
model
conceptu
divers
time
lethal
mutagenesi
error
threshold
remark
counterintuit
propos
model
deni
connect
error
threshold
quasispeci
theori
extinct
virus
enhanc
mutagenesi
one
model
discuss
h
tejero
colleagu
suggest
error
catastroph
could
occur
presenc
lethal
genotyp
propos
consid
peculiar
experimentalist
proven
incorrect
takeuchi
hogeweg
see
also
refer
public
tejero
et
al
model
suggest
lethal
mutagenesi
unrel
error
threshold
defin
extinct
threshold
mean
mutat
rate
viral
popul
goe
extinct
rather
counterintuit
propos
error
threshold
caus
surviv
flattest
mean
domin
genom
low
replic
capac
high
toler
mutat
robust
figur
represent
viru
entri
error
catastroph
error
threshold
relationship
quasispeci
theori
mutant
spectrum
top
replic
mutat
rate
maximum
compat
mainten
genet
inform
max
popul
remain
stabl
viru
surviv
mutant
spectrum
first
one
replic
mutat
rate
exce
highest
toler
max
mainten
genet
inform
consequ
progress
deterior
viral
function
genom
replic
repres
genom
drawn
discontinu
line
number
increas
replic
proce
condit
max
system
collaps
total
loss
inform
loss
viru
ident
transit
replicationincompet
sequenc
viru
extinct
box
mutant
distribut
includ
basic
mathemat
formula
error
threshold
select
superior
master
sequenc
mutant
spectrum
n
chain
length
replic
genom
n
max
maximum
length
whose
inform
maintain
replic
mutat
rate
mathemat
deriv
error
threshold
relationship
see
schuster
see
text
connect
error
threshold
lethal
mutagenesi
trend
antivir
strategi
would
hinder
viru
extinct
tejero
et
al
see
section
chapter
advantag
flattest
fit
landscap
c
peral
care
review
main
experiment
result
obtain
laboratori
molecular
event
accompani
transit
toward
viru
extinct
tri
harmon
experiment
observ
realist
signific
theoret
model
review
tejero
et
al
mainstream
experiment
result
summar
follow
first
studi
extens
carri
jj
holland
laboratori
confirm
connect
mutagen
activ
decreas
viral
infect
show
low
viral
load
low
viral
fit
favor
viru
extinct
loeb
et
al
sierra
et
al
low
popul
number
increas
risk
extinct
accept
type
organ
circumst
known
ale
effect
follow
import
discov
eri
nucleosid
analog
ribavirin
mutagen
pv
crotti
et
al
observ
ribavirin
decreas
pvspecif
infect
ratio
infect
amount
viral
rna
crotti
et
al
decreas
specif
infect
togeth
increas
mutat
frequenc
consid
standard
way
distinguish
lethal
mutagenesi
mere
inhibit
box
mean
decreas
specif
infect
exclus
lethal
mutagenesi
also
document
result
codon
deoptim
section
chapter
viral
clone
subject
mani
plaquetoplaqu
transfer
section
chapter
subsequ
studi
grandep
erez
colleagu
document
treatment
cell
persist
infect
lcmv
fu
result
decreas
infect
preced
decreas
viral
rna
see
section
mutagen
mechan
ribavirin
fu
result
suggest
class
replicationcompet
rna
lead
infecti
viru
gener
low
viral
load
low
viral
fit
favor
extinct
transit
toward
extinct
viral
popul
decreas
specif
infect
increas
mutant
spectrum
complex
movement
toward
usual
unfavor
region
sequenc
space
maintain
invari
consensu
sequenc
reduct
viral
load
per
se
mechan
viru
extinct
load
decreas
mutagen
agent
may
extinguish
viru
decreas
inhibitor
may
virus
display
differ
replic
featur
respond
mutagen
agent
similar
way
strategi
gener
applic
provid
virusspecif
mutagen
agent
avail
use
mutagen
antivir
agent
valid
vivo
fumedi
transit
toward
viral
extinct
theoret
model
develop
manrubia
predict
defect
genom
term
defector
requir
achiev
lcmv
extinct
limit
mutagen
intens
fu
grandep
erez
et
al
propos
loss
viral
infect
due
action
defect
genom
produc
mutagen
agent
term
lethal
defect
model
viru
extinct
consist
sever
observ
extinct
virus
review
domingo
et
al
diagnost
test
loss
infect
preced
loss
viral
rna
fig
lethal
defect
regard
extrem
outcom
interf
interact
exert
among
compon
mutant
spectrum
mutat
load
increas
compar
section
chapter
studi
grandep
erez
manrubia
colleagu
distinguish
two
pathway
virus
follow
subject
mutagenesi
lethal
defect
low
mutagen
intens
overt
lethal
high
mutagen
intens
fig
recapitul
understand
step
involv
mutagenesisdriven
viru
extinct
import
qualif
sharp
boundari
exist
lethal
defect
overt
lethal
phase
studi
footandmouth
diseas
viru
fmdv
provid
support
lethal
defect
phase
extinct
defect
fmdv
rna
inhibit
replic
standard
fmdv
rna
specif
manner
coelectropor
cell
peral
et
al
specif
mean
defect
fmdv
rna
inhibit
replic
relat
encephalomyocard
viral
rna
specif
also
evidenc
loss
interf
activ
defector
genom
introduct
mutat
prevent
rna
replic
requir
replic
defect
rna
suggest
suffici
amount
express
protein
need
interfer
peral
et
al
result
consist
enhanc
also
specif
interf
activ
exert
mutagen
fmdv
rna
gonz
alezl
opez
et
al
thu
avail
evid
suggest
mutant
rnasdwhos
frequenc
mutat
load
increas
mutagenesi
proceedsdadvers
affect
figur
summari
main
experiment
observ
upon
mutagenesi
viral
popul
top
mutagenesi
result
expans
mutant
spectrum
red
gaussian
distribut
may
skew
real
popul
increas
averag
number
mutat
per
nucleotid
decreas
infecti
rna
blue
thin
column
specif
valu
depend
experiment
system
bottom
increas
averag
number
nucleotid
lead
mainten
viral
rna
discontinu
curv
despit
loss
infect
blue
curv
box
bottom
underlin
major
chang
underw
viral
genom
result
mutagenesi
point
also
includ
box
figur
reproduc
domingo
e
sheldon
j
peral
c
viral
quasispeci
evolut
microbiol
mol
biol
rev
permiss
american
societi
microbiolog
washington
dc
usa
replic
nonmut
rna
coexist
replic
ensembl
major
molecular
event
recogn
lethal
defect
phase
fig
infecti
fmdv
rna
retriev
mutagen
popul
dilut
plaqu
isol
display
decreas
replic
fit
lower
infect
rel
parent
nonmutagen
viru
associ
eightfold
increas
mutat
frequenc
result
reinforc
complex
event
lethal
mutagenesi
confirm
fit
may
impair
clone
transient
surviv
mutagen
activ
suggest
overlap
lethal
defect
overt
lethal
phase
drawn
fig
consid
theoret
model
light
experiment
result
first
propos
interfer
substitut
transact
protein
line
earli
descript
fit
deterior
cell
due
collaps
interdepend
nucleic
acid
protein
tran
network
connect
process
age
orgel
case
lethal
defect
effect
mutat
calibr
keep
mind
multifunct
natur
viral
protein
section
chapter
protein
defect
jeopard
activ
protein
interact
tran
network
collaps
domino
effect
possibl
influenc
topolog
network
interact
among
genom
mainten
popul
stabil
larg
unexplor
possibl
briefli
address
close
chapter
notion
viral
mutagenesi
promot
drift
sequenc
space
shown
direct
amplif
urich
genom
sequenc
fmdv
subject
ribavirin
mutagenesi
peral
et
al
main
effect
ribavirin
acceler
occup
urich
region
sequenc
space
presum
due
tendenc
purin
analog
produc
excess
g
c
u
transit
section
analysi
number
type
mutat
suggest
uenrich
portion
sequenc
space
detriment
viral
fit
movement
toward
unfavor
region
sequenc
space
also
suggest
mutant
spectrum
analys
fmdv
subject
fu
mutagenesi
virus
subject
mutagen
agent
grandep
erez
et
al
grandep
erez
et
al
agudo
et
al
ortegaprieto
et
al
view
evid
theoret
model
lethal
mutagenesi
propos
deloc
genom
popul
sequenc
space
fit
experiment
result
figur
scheme
step
involv
viru
extinct
enhanc
mutagenesi
graph
includ
basic
element
quasispeci
fidel
horizont
black
arrow
span
entir
possibl
rang
copi
fidel
valu
valu
perfect
copi
fidel
mutat
incompat
evolut
life
complet
infidel
mutat
norm
incompat
mainten
genet
inform
top
horizont
axi
four
success
recogn
step
reach
decreas
copi
fidel
repres
region
mainten
dynam
quasispeci
region
lethal
defect
region
overt
lethal
final
cross
error
threshold
red
arrow
last
transit
visual
viral
genom
sequenc
degener
random
sequenc
transit
inform
noinform
balanc
drawn
bottom
symbol
influenc
may
either
favor
prevent
viru
extinct
lethal
mutagenesi
error
threshold
extinct
specif
model
base
advantag
flattest
predict
absenc
extinct
tejero
et
al
realiti
predict
extinct
real
viru
mutagenesisdriven
astray
walk
sequenc
space
absenc
domin
master
sequenc
produc
increas
number
defect
genom
lethal
defect
unfavor
region
sequenc
space
urich
region
promot
ribavirin
net
result
lethal
defect
also
increasingli
frequent
hit
lethal
portion
space
overt
lethal
phase
shown
fig
thu
theoret
model
base
genom
sequenc
deloc
fit
experiment
observ
deloc
turn
antivir
strategi
discuss
next
section
pioneer
experi
jj
holland
colleagu
demonstr
advers
effect
mutagen
agentsdinclud
base
analog
fu
nucleosid
analog
one
product
infecti
pv
vsv
progeni
holland
et
al
lee
et
al
investig
follow
sever
other
examin
effect
base
nucleosid
analog
viru
surviv
studi
anim
virus
summar
tabl
illustr
virus
display
divers
replic
strategi
positiveand
negativestrand
rna
virus
retrovirus
vulner
increas
mutat
rate
investig
cell
cultur
anim
host
employ
mutagen
base
nucleosid
analog
convert
intracellularli
nucleosidetriphosph
form
latter
incorpor
rna
next
round
templat
copi
give
rise
misincorpor
point
mutat
case
rna
chain
termin
mutagenesi
mainli
due
ambigu
pair
mutagen
base
standard
nucleotid
format
watsoncrick
wobbl
base
pair
basepair
structur
fu
g
drawn
fig
sower
et
al
yu
et
al
ribavirin
favipiravir
fig
crotti
et
al
jin
et
al
see
section
chapter
standard
watsoncrick
wobbl
base
pair
possibl
point
mutat
gener
consequ
fu
ribavirin
incorpor
viral
genom
replic
depict
fig
respect
figur
repres
frequent
caus
success
analog
incorpor
subsequ
event
upon
copi
positiveand
negativestrand
viral
rna
although
pathway
equal
applic
dna
case
deoxynucleotid
analog
scheme
serv
guid
anticip
possibl
mutat
type
induc
analog
provid
basepair
behavior
investig
physicochem
procedur
consid
mutat
prefer
may
affect
environment
factor
mutant
repertoir
produc
mutagen
nucleotid
may
influenc
structur
microenviron
viral
polymeras
neighborhood
site
determin
base
pair
templat
incom
nucleotid
although
polymeras
share
gener
structur
featur
nucleotid
discrimin
incorpor
subtli
depend
natur
surround
amino
acid
templateprim
nucleotid
sequenc
ionic
composit
see
section
chapter
polymeras
structur
fidel
mutant
section
interact
viral
polymeras
associ
resist
mutagen
nucleotid
sever
virus
mutant
spectra
produc
upon
replic
presenc
fu
includ
excess
g
u
c
g
c
u
transit
trend
antivir
strategi
agudo
et
al
bia
favor
g
u
c
mutat
suggest
fu
behav
u
rather
c
incorpor
viral
polymeras
fu
templat
residu
tend
behav
c
rather
u
fig
studi
sever
virus
indic
ribavirin
mutagenesi
yield
mutant
spectra
excess
g
c
u
g
u
c
fig
although
incorpor
bia
depend
viru
crotti
et
al
day
et
al
chung
et
al
agudo
et
al
moreno
et
al
dietz
et
al
ortegaprieto
et
al
galli
et
al
among
studi
review
mutagen
activ
ribavirin
see
crotti
et
al
beaucourt
vignuzzi
effect
mutagen
nucleotid
analog
may
influenc
posit
occupi
templat
shown
earli
sitedirect
mutagenesi
experi
bacteriophag
qb
rna
perform
r
flavel
c
weissmann
colleagu
chapter
pyrimidin
analog
n
hydroxi
cmp
present
extracistron
posit
direct
incorpor
gmp
slightli
effici
amp
posit
incorpor
amp
threefold
higher
gmp
compar
flavel
et
al
domingo
et
al
new
mutagen
nucleotid
current
investig
potenti
lethal
mutagen
virus
harki
et
al
harki
et
al
harki
et
al
graci
cameron
dapp
et
al
vivetboud
et
al
among
studi
activ
research
appli
drug
deriv
use
antibacteri
anticanc
therapi
lethal
mutagenesi
virus
drug
reposit
drug
repurpos
see
section
chapter
lm
manski
associ
pioneer
effort
search
new
antiretrovir
agent
well
studi
new
combin
therapi
base
lethal
mutagenesi
dapp
et
al
dapp
et
al
bonnac
et
al
rawson
manski
studi
joint
effect
apolipoprotein
b
mrna
edit
complex
mutat
spectrum
result
reveal
unexpect
chang
mutat
trend
particularli
increas
g
transit
decreas
g
c
transvers
mutat
type
promin
alon
dapp
et
al
also
defin
new
class
antivir
agent
term
mild
mutagen
exhibit
limit
mutagen
activ
may
enhanc
antivir
effect
inhibitor
rawson
et
al
may
interest
explor
possibl
mild
mutagen
activ
downward
arrow
indic
standard
base
copi
r
incorpor
block
left
explain
consequ
incorpor
r
instead
either
minu
strand
second
row
plu
strand
third
row
block
right
indic
consequ
incorpor
r
instead
g
either
minu
strand
second
row
plu
strand
third
row
box
bottom
indic
type
mutat
expect
mutant
spectrum
see
text
refer
analog
shown
sofosbuvir
zika
viru
sacramento
et
al
complex
interact
among
mutagen
inhibitor
mutagen
infect
cell
still
poorli
understood
studi
provid
evid
sequenti
inhibitormutagen
treatment
may
advantag
correspond
combin
fundament
avoid
interfer
deriv
simultan
presenc
mutagen
inhibitor
viral
replic
section
investig
summar
previou
section
carri
cell
cultur
anim
experi
clinic
trial
provid
proof
principl
feasibl
antivir
intervent
base
lethal
mutagenesi
vivo
jc
de
la
torr
colleagu
document
administr
fu
mice
prevent
establish
persist
lcmv
infect
anim
ruizjarabo
et
al
ji
mullin
colleagu
carri
first
phase
ii
clinic
trial
use
lethal
mutagenesi
administ
deoxycitidin
prodrug
deoxycitidin
infect
volunt
previous
treat
antiretrovir
agent
mullin
et
al
reduct
viral
load
increas
averag
mutat
frequenc
note
treat
patient
howev
mutat
like
occur
cours
treatment
predominantli
g
g
transit
expect
basepair
behavior
pyrimidin
analog
studi
valid
lethal
mutagenesi
antivir
approach
human
diseas
purin
analog
favipiravir
base
pair
behavior
shown
fig
act
effect
antinoroviru
agent
mous
model
featur
diagnost
lethal
mutagenesi
increas
mutat
frequenc
decreas
specif
infect
box
favipiravir
deriv
interest
compound
share
ribavirin
broad
antivir
spectrum
activ
favipiravir
proven
effect
sever
virus
vivo
includ
west
nile
infect
mice
hamster
morrey
et
al
lethal
inhal
rift
valley
fever
viru
rat
carolin
et
al
highli
pathogen
iv
mice
kiso
et
al
still
open
question
act
lethal
mutagen
vivo
system
iv
cell
cultur
baranovich
et
al
noroviru
cell
cultur
vivo
favipiravir
mutagenesi
discuss
come
section
ribavirin
use
mani
year
combin
pegyl
ifna
standard
care
treatment
hcv
infect
mchutchison
et
al
cum
et
al
di
biscegli
et
al
clear
whether
lethal
mutagenesi
part
antihcv
activ
ribavirin
studi
favor
mutagen
activ
viru
other
gerotto
et
al
querenghi
et
al
sookoian
et
al
dixit
et
al
asahina
et
al
chevaliez
et
al
lutchman
et
al
perelson
layden
cueva
et
al
dietz
et
al
studi
dietz
et
al
involv
deep
sequenc
analys
hcv
patient
subject
ribavirin
monotherapi
viru
show
mutat
bia
expect
ribavirin
mutagenesi
suggest
cell
cultur
experi
concentr
ribavirin
use
attain
vivo
measur
concentr
ribavirin
nucleotid
hcv
replic
complex
avail
conclud
lethal
mutagenesi
vivo
complic
deriv
multipl
mechan
drug
actiondth
case
ribavirin
ribavirin
concentr
vivo
incompat
mutagenesi
also
broad
rang
ribavirin
concentr
human
serum
report
treatment
discuss
refer
ortegaprieto
et
al
furthermor
sever
reason
miss
mutagen
activ
vivo
current
analyt
procedur
ribavirin
produc
transient
expans
follow
compress
mutant
spectrum
complex
model
studi
fmdv
cell
cultur
ojosnegro
et
al
peral
et
al
fig
possibl
interpret
mutat
load
due
ribavirin
mutagenesi
surpass
critic
valu
increasingli
defect
genom
ceas
contribut
progeni
result
mutant
spectrum
compress
addit
variat
fmdv
mutant
spectrum
complex
observ
upon
mutagen
treatment
interrupt
discuss
ojosnegro
et
al
model
studi
render
unsurpris
consist
expans
hcv
mutant
spectra
observ
patient
subject
ribavirinbas
treatment
chronic
infect
untreat
patient
compar
eg
farci
et
al
duffi
et
al
sullivan
et
al
ramachandran
et
al
palmer
et
al
thu
even
ribavirin
treatment
alter
mutant
spectrum
complex
may
miss
depend
time
treatment
onset
viral
sampl
obtain
also
necessari
quantifi
amount
viral
rna
ensur
sequenc
analys
either
standard
molecular
cloningsang
sequenc
deep
sequenc
provid
faith
represent
biolog
sampl
see
section
chapter
view
unlik
mutagen
activ
readili
observ
cell
cultur
may
total
absent
bear
relationship
activ
ribavirin
vivo
even
though
mechan
ribavirin
action
may
also
play
role
overal
antivir
activ
mutagen
activ
ribavirin
document
cell
cultur
hcv
subgenom
replicon
contrera
et
al
zhou
et
al
kanda
et
al
ortegaprieto
et
al
albeit
except
kato
et
al
mori
et
al
main
problem
interpret
mechan
antihcv
activ
ribavirin
vivo
antivir
agent
act
sever
nonexclus
mechan
includ
immunomodulatori
activ
enhanc
antivir
respons
hultgren
et
al
ning
et
al
ii
upregul
express
gene
relat
ifn
signal
pathway
zhang
et
al
feld
et
al
iii
deplet
intracellular
triphosph
gtp
level
associ
inhibit
inosinemonophosph
dehydrogenas
impdh
enzym
figur
expans
compress
fmdv
mutant
spectrum
follow
ribavirin
mutagenesi
biolog
clone
fmdv
left
subject
serial
passag
presenc
increas
concentr
ribavirin
mm
size
three
sphere
quantifi
approxim
manner
complex
mutant
spectrum
follow
averag
distanc
paramet
use
quantifi
genom
subpopul
partit
analysi
quasispeci
paq
cluster
procedur
baccam
et
al
amplitud
mutant
spectrum
increas
first
compress
signific
extent
scheme
base
data
report
ojosnegro
et
al
possibl
interpret
implic
discuss
text
convert
inosinemonophosph
xanthosinemonophosph
gtp
biosynthesi
pathway
ribavirinmonophosph
rmp
streeter
et
al
mutagen
effect
reduc
inosin
triphosph
itp
pyrophosphatas
activ
associ
common
allel
variant
human
om
et
al
iv
inhibit
mrna
cap
format
goswami
et
al
v
inhibit
viral
polymeras
independ
mutagen
activ
eriksson
et
al
wray
et
al
toltzi
et
al
fernandezlarsson
et
al
maag
et
al
bougi
bisaillon
vi
lethal
mutagenesi
evidenc
sever
rna
virus
studi
list
tabl
virus
leyssen
et
al
leyssen
et
al
kim
lee
gener
review
antivir
properti
ribavirin
see
snell
graci
cameron
parker
beaucourt
vignuzzi
easi
separ
inhibitori
mutagen
activ
exert
mutagen
base
nucleosid
analog
intracellular
deriv
inhibit
may
consequ
mutagenesi
inhibit
mutagenesi
may
two
total
separ
mode
action
case
antivir
activ
fu
fmdv
possibl
show
inhibit
uridylyl
primer
protein
vpg
initi
step
picornaviru
rna
synthesi
futp
addit
mutagen
activ
futp
rna
elong
case
ribavirin
situat
complex
particip
sever
six
mechan
list
previou
paragraph
antihcv
activ
includ
human
allel
potenti
mutagenesi
om
et
al
consid
particular
would
interest
reexamin
evid
inhibit
viral
polymeras
ascertain
inhibit
independ
mutagen
activ
interest
possibl
inadvert
lethal
mutagenesi
might
mode
action
broadspectrum
antivir
agent
use
decad
tradit
consid
standard
nonmutagen
inhibitor
favipiravir
discov
furuta
colleagu
effect
antivir
agent
iv
furuta
et
al
furuta
et
al
proven
effect
broad
rang
rna
virus
document
inhibitori
rna
chain
termin
mutagen
activ
cell
cultur
vivo
sever
studi
includ
tabl
review
peral
et
al
signific
result
report
x
de
lamballeri
colleagu
show
experiment
infect
macaqu
ebola
viru
protect
activ
favipiravir
confer
drug
dose
evok
viru
mutagenesi
guedj
et
al
ongo
studi
favipiravir
mani
other
ribavirin
consid
classic
antivir
design
elev
lethal
mutagenesi
rank
realist
antivir
strategi
concept
offer
promis
addit
mutagen
nucleotid
perhap
new
drug
design
modifi
polymeras
fidel
without
nucleotid
analog
emerg
viral
infect
know
go
happen
despit
incapac
anticip
establish
infect
new
treatment
option
may
becom
necess
type
antivir
agent
howev
preclin
clinic
assay
preced
licens
human
use
discuss
peral
et
al
challeng
remain
lethal
mutagensmedi
select
mutant
virus
display
resist
either
mutagen
activ
consequ
mutagenesi
lethal
mutagenesi
vivo
complic
deriv
multipl
mechan
drug
actiondth
case
ribavirin
viru
resist
mutagen
agent
multipl
mechan
evid
abort
escap
pathway
took
decad
use
ribavirin
obtain
first
resist
mutant
use
sindbi
viru
mycophenol
acid
nonmutagen
inhibitor
impdh
select
mycophenol
acidresist
mutant
display
crossresist
ribavirin
scheidel
et
al
scheidel
stollar
decad
later
first
ribavirinresist
mutant
polioviru
select
laboratori
pfeiffer
kirkegaard
hcv
patient
ribavirin
monotherapi
describ
young
et
al
subsequ
work
character
viral
mutant
resist
mutagen
agent
particularli
ribavirin
fu
pfeiffer
kirkegaard
sierra
et
al
agudo
et
al
levi
et
al
arriba
et
al
feigelstock
et
al
domingocalap
et
al
sadeghipour
et
al
zeng
et
al
zeng
et
al
among
studi
major
overal
conclus
investig
virus
develop
resist
mutagen
nucleotid
analog
nonmutagen
inhibitor
sever
mechan
resist
mutagen
nucleotid
analog
describ
major
one
list
box
broadli
divid
two
main
categori
modif
viral
polymeras
modif
protein
first
substitut
describ
confer
ribavirin
resist
pv
polymeras
result
increas
polymeras
templatecopi
fidel
studi
pv
harbor
mutat
instrument
show
relev
mutant
spectrum
complex
viru
adapt
pfeiffer
kirkegaard
vignuzzi
et
al
see
section
chapter
studi
establish
import
concept
maintain
adequ
fit
good
surviv
probabl
viru
popul
must
keep
substitut
increas
gener
copi
fidel
enzym
substitut
specif
limit
incorpor
mutagen
nucleotid
substitut
modul
rel
incorpor
standard
nucleotid
amino
acid
substitut
viral
protein
substitut
nonstructur
viral
protein
particip
viral
replic
modifi
polymeras
fidel
modul
nucleotid
incorpor
combin
mechan
fitnessenhanc
mutat
unrel
resist
per
se
contribut
express
stabil
resist
trait
virolog
studi
involv
base
nucleosid
analog
rather
nucleosidetriphosph
assum
least
mechan
describ
date
base
nucleosid
convert
nucleosidetriphosph
deriv
respons
mutagen
activ
see
text
refer
genom
heterogen
within
suitabl
rang
low
divers
impair
adapt
high
divers
may
approach
popul
extinct
threshold
smith
denison
zeng
et
al
sever
studi
demonstr
attenu
phenotyp
associ
lowor
highfidel
viral
mutant
borderia
et
al
rai
et
al
clinic
set
maintain
mutant
spectra
virus
within
suitabl
amplitud
rang
one
predictor
viral
surviv
progress
toward
diseas
section
chapter
amino
acid
substitut
polymeras
relat
virus
may
differ
phenotyp
effect
ribavirin
resist
fidelityenhanc
pv
substitut
obtain
independ
two
differ
laboratori
pfeiffer
kirkegaard
castro
et
al
suggest
pv
may
restrict
number
mutat
attain
ribavirin
resist
despit
ampl
evid
virus
gener
display
altern
mutat
pathway
toward
resist
nonmutagen
inhibitor
section
chapter
gener
multipl
pathway
fit
gain
et
al
nguyen
et
al
cabanilla
et
al
arena
et
al
fmdv
whose
polymeras
close
relat
pv
ferrerorta
et
al
passag
presenc
ribavirin
replac
one
equival
pv
select
instead
substitut
becam
domin
confer
ribavirin
resist
sierra
et
al
mutant
fmdv
encod
construct
sitedirect
mutagenesi
display
strong
select
disadvantag
rel
standard
viru
partial
compens
presenc
mutant
revert
upon
passag
cell
cultur
fmdv
substitut
stabl
comparison
enzymolog
properti
fmdv
polymeras
either
indic
impair
rna
bind
rna
polymer
incorpor
rmp
rna
therefor
despit
potenti
benefit
replic
fmdv
presenc
ribavirin
select
would
abort
despit
site
substitut
separ
network
interact
allow
crossinflu
two
site
effect
catalyt
domain
enzym
still
fmdv
amino
acid
substitut
opposit
effect
templat
copi
fidel
depend
viral
serotyp
sequenc
context
li
et
al
polymeras
substitut
may
evok
resist
multipl
mutagen
nucleotid
crossresist
ribavirin
nucleosid
deriv
st
loui
enceph
viru
mutant
griesem
et
al
thu
due
distanc
effect
subtl
sequencedepend
network
connect
among
residu
within
polymeras
molecul
amino
acid
replac
may
dispar
unpredict
effect
behavior
close
relat
polymeras
substitut
fmdv
offer
exampl
mutagen
resist
limit
incorpor
rmp
viral
rna
without
signific
alter
gener
templatecopi
fidel
enzym
sierra
et
al
box
fit
mutant
fmdv
rel
standard
viru
presenc
mm
ribavirin
absenc
ribavirin
valu
repres
select
strength
viru
resist
mutagen
agent
multipl
mechan
evid
abort
escap
pathway
substitut
f
ribavirin
f
ribavirin
calcul
describ
section
chapter
select
strength
confer
substitut
suffici
maintain
substitut
one
viru
respond
higher
ribavirin
concentr
passag
mutant
viru
presenc
larger
concentr
ribavirin
result
select
two
addit
substitut
yield
viru
tripl
substitut
tripl
mutant
term
ssi
select
strength
tripl
mutant
measur
presenc
mm
ribavirin
higher
select
strength
confer
alon
significantli
salient
biochem
featur
display
mutant
polymeras
restrict
incorpor
rmp
strongli
opposit
c
opposit
u
determin
sever
vitro
incorpor
assay
consequ
replic
presenc
ribavirin
mutant
ssi
could
maintain
balanc
differ
transit
type
measur
ratio
g
c
u
g
u
c
mutat
typic
standard
viru
replic
absenc
mutagen
see
fig
ribavirinmedi
mutat
pathway
modul
mechan
associ
substitut
fmdv
one
mutagen
resist
mechan
list
box
modul
transit
type
allow
viru
maintain
typic
mutant
spectrum
complex
correspond
adapt
interestingli
substitut
contribut
select
advantag
presenc
high
mm
ribavirin
concentr
transitionmodul
phenotyp
alreadi
acquir
box
also
list
mutat
contribut
mutagen
escap
increas
fit
without
bona
fide
resist
mutat
comparison
fitnessenhanc
mutat
describ
antivir
resist
chapter
effect
fmdv
suggest
mutat
divid
two
class
increas
fit
gener
presenc
mutagen
even
presenc
rang
mutagen
concentr
analys
mutant
spectra
produc
fmdv
standard
ssi
absenc
presenc
ribavirin
suggest
bia
favor
g
c
u
may
detriment
viru
presum
may
modifi
rna
protein
composit
probabl
also
increas
frequenc
defect
genom
latter
suggest
presenc
stop
codon
one
clone
mutagen
standard
viru
popul
threedimension
structur
ribavirinresist
polymeras
reveal
alter
ntermin
region
affect
site
belong
nuclear
local
signal
nl
present
fmdv
sanchezaparicio
et
al
amino
acid
substitut
within
nl
diminish
transport
nucleu
function
precursor
intermedi
proteas
also
modifi
templat
bind
nucleotid
recognit
properti
ferrerorta
et
al
de
la
higuera
et
al
interestingli
replac
within
nl
increas
incorpor
rmp
rel
standard
substrat
suggest
structur
alter
viral
polymeras
may
enhanc
vulner
virus
nucleotid
analog
result
effect
amino
acid
substitut
within
nl
fmdv
emphas
multifunct
natur
viral
polymeras
line
recogn
multifunction
mani
viral
protein
featur
increas
vulner
lethal
mutagenesi
despit
uncertainti
repeatedli
expos
book
depend
enzym
behavior
protein
templat
sequenc
context
behavior
modif
due
trend
antivir
strategi
introduct
addit
amino
acid
substitut
etc
envisag
structurebas
design
new
drug
could
found
tailor
viral
polymeras
enhanc
incorpor
mutagen
nucleotid
could
ad
exist
nucleotid
analog
formul
new
antivir
combin
comparison
sever
amino
acid
group
amino
acid
substitut
fmdv
involv
ribavirin
resist
sierra
et
al
agudo
et
al
zeng
et
al
ferrerorta
et
al
suggest
multipl
case
even
independ
evolutionari
pathway
viru
achiev
resist
mutagen
agent
multipl
pathway
toward
resist
standard
nonmutagen
inhibitor
case
pv
differ
ribavirin
resist
substitut
would
expect
independ
viral
lineag
subject
rang
ribavirin
concentr
modul
nucleotid
incorpor
also
mechan
fmdv
resist
fu
singl
polymeras
substitut
prevent
excess
g
u
c
transit
induc
analog
de
la
higuera
et
al
ad
advantag
select
mutant
alter
mutat
spectrum
may
lead
viru
attenu
differ
host
warmbrod
et
al
thu
ampl
evid
sever
viral
system
polymeras
substitut
modul
nucleotid
incorpor
modul
per
se
mechan
resist
lethal
mutagenesi
viral
polymeras
determin
templatecopi
fidel
viral
replic
machineri
consist
complex
sever
viral
host
protein
shown
protein
polymeras
also
contribut
polymeras
fidel
resist
mutagen
agent
box
tripl
ssi
ribavirinresist
mutant
fmdv
passag
presenc
high
ribavirin
concentr
popul
includ
replac
nonstructur
protein
select
agudo
et
al
possibl
readthrough
protein
bacteriophag
qb
may
contribut
resist
suggest
studi
e
l
azaro
colleagu
arriba
et
al
although
limit
amino
acid
substitut
viral
replicas
confer
resist
cabanilla
et
al
small
nonenzymat
coronaviru
nonstructur
protein
involv
maintain
replic
fidel
viru
smith
et
al
two
substitut
protein
hcv
replicon
confer
lowlevel
resist
ribavirin
pfeiffer
kirkegaard
case
dna
bacteriophag
encod
polymeras
fu
resist
achiev
substitut
viruscod
lysi
protein
pereiragomez
sanjuan
propos
delay
cell
lysi
increas
amount
progeni
viru
per
cell
limit
number
infecti
cycl
reduc
chanc
mutagenesi
also
discuss
section
chapter
regard
gener
molecular
mechan
antivir
resist
therefor
current
evid
anticip
multipl
adapt
mechan
viru
resist
mutagen
nucleotid
necessarili
confin
polymeras
document
standard
inhibitor
howev
interest
possibl
initi
advantag
mutagen
agent
standard
inhibitor
imped
select
resist
mutant
justifi
suggest
current
therapeut
altern
base
lethal
mutagenesi
discuss
viru
extinct
outcom
replac
viru
subpopul
tempo
mode
mutat
acquisit
gener
consider
deriv
observ
describ
previou
section
worth
comment
extinct
viru
consequ
reduct
viral
viru
extinct
outcom
replac
viru
subpopul
tempo
mode
mutat
acquisit
load
insuffici
r
valu
ensur
celltocel
transmiss
sustain
infect
see
section
chapter
concept
r
simpl
movement
sequenc
space
even
increas
mutat
load
replic
genom
result
combin
sever
influenc
specif
circumst
kinet
accumul
mutat
viral
genom
consid
point
turn
studi
n
parient
c
peral
colleagu
show
given
reduct
viral
load
achiev
mutagenesi
suffici
drive
fmdv
toward
extinct
reduct
achiev
inhibit
lead
viru
extinct
parient
et
al
peral
et
al
main
differ
mutagenesi
dynam
process
genom
variat
reduct
viral
load
inhibit
basic
static
process
regard
incorpor
mutat
decreas
viral
load
alreadi
taken
place
viru
becom
vulner
mutagenesi
sierra
et
al
movement
sequenc
space
norm
viru
replic
evolut
independ
subject
increas
mutagenesi
urich
genom
subpopul
becam
domin
upon
passag
fmdv
presenc
ribavirin
also
exist
standard
viral
popul
albeit
lower
level
peral
et
al
main
effect
ribavirin
shift
domin
part
mutant
spectrum
urich
region
shift
may
increas
presenc
defect
genom
includ
defector
interfer
replic
standard
viru
section
encount
one
main
departur
introduc
quasispeci
understand
viru
evolut
replac
genom
subpopul
other
case
extinct
movement
consist
replac
standard
subpopul
other
lie
unfavor
portion
sequenc
space
express
anoth
manner
mutagenesi
forc
uncontrol
fit
gradientmedi
reloc
sequenc
space
mutat
load
calcul
number
mutat
incorpor
individu
genom
predictor
surviv
extinct
depend
locat
mutat
accumul
mutat
may
reduc
fit
robust
effect
addit
mutat
section
chapter
still
allow
replic
compet
fmdv
clone
subject
multipl
plaquetoplaqu
transfer
accumul
mutat
rate
mutat
per
passag
impli
viabl
fmdv
genom
accumul
number
mutat
equival
mutat
frequenc
substitut
per
nucleotid
et
al
lower
mutat
frequenc
suffici
extinguish
viral
clone
upon
passag
presenc
mutagen
agent
tempo
mode
accumul
mutat
determin
factor
e
l
azaro
colleagu
show
enhanc
qb
replic
plaqu
develop
drove
viru
extinct
growth
liquid
cultur
medium
unless
mutagenresist
qb
select
casesgonzalez
et
al
arriba
et
al
experiment
design
plaqu
transfer
transfer
viral
particl
capabl
develop
visibl
plaqu
cell
monolay
rescu
matter
mani
companion
left
behind
extinguish
appli
select
power
contrast
mutagenesi
without
interven
plaqu
isol
mean
recov
viabl
minor
survivor
includ
design
rare
potenti
survivor
cluster
mutat
aris
transient
suppress
surround
mutant
spectrum
perish
due
next
round
mutagenesi
thu
even
benefici
mutat
like
aris
lowfit
genom
contribut
surviv
minim
continu
mutagen
environ
critic
point
predict
viru
extinct
close
error
extinct
trend
antivir
strategi
threshold
viru
replic
take
place
evid
dna
genom
whose
replic
catalyz
highfidel
dna
polymeras
may
resist
transient
increas
mutat
rate
even
benefit
cuppl
miller
sol
e
deisboeck
springman
et
al
thu
viral
extinct
enhanc
mutagenesi
condit
sever
factor
relat
mainli
basal
replic
paramet
viru
kinet
mutagenesi
test
paradigm
gener
advantag
combin
therapi
monotherapi
initi
experi
design
studi
efficaci
combin
mutagen
agent
antivir
inhibitor
result
document
extinct
highfit
fmdv
could
achiev
combin
mutagen
agent
nonmutagen
inhibitor
mutagen
agent
alon
parient
et
al
parient
et
al
tapia
et
al
despit
expect
result
addit
experi
pursu
c
peral
fmdv
demonstr
respons
viru
combin
action
inhibitor
mutagen
agent
bit
complex
initi
thought
product
infect
viral
rna
measur
cours
viral
passag
presenc
inhibitor
guanidinium
chlorid
alon
ribavirin
alon
combin
guanidinium
chlorid
ribavirin
initi
passag
presenc
guanidinium
chlorid
follow
passag
presenc
ribavirin
alon
fig
result
quantif
fmdv
progeni
sensit
rtpcr
test
viru
extinct
document
design
consist
administ
guanidin
alon
first
follow
addit
passag
presenc
ribavirin
alon
effect
reduc
progeni
product
drive
viru
toward
extinct
fig
peral
et
al
manrubia
develop
theoret
model
whose
main
paramet
concentr
standard
defect
virus
sensit
resist
inhibitor
viral
mutat
rate
rate
gener
inhibitorresist
mutant
number
standard
defect
progeni
genom
number
infect
cell
infecti
cycl
per
cell
model
describ
peral
et
al
iranzo
et
al
explain
advantag
sequenti
inhibitormutagen
administr
protocol
correspond
combin
term
replic
paramet
intens
mutagenesi
inhibitor
mutagen
present
togeth
viral
replic
joint
influenc
viral
rna
may
jeopard
viru
extinct
possibl
mechan
summar
box
notabl
presenc
mutagen
may
transient
increas
frequenc
inhibitorresist
mutant
therefor
favor
viru
escap
treatment
failur
second
mechan
simultan
presenc
inhibitor
mutagen
imped
viru
extinct
presenc
inhibitor
rna
defector
gener
mutagenesi
viral
rna
interfer
viral
replic
reason
defector
replic
need
lethal
defect
section
presum
replic
increas
amount
rna
encod
transact
substitut
protein
detriment
viru
life
cycl
respons
lethal
defect
grandep
erez
et
al
advantag
sequenti
inhibitormutagen
administr
also
evidenc
lcmv
take
advantag
doubl
inhibitor
mutagen
charact
ribavirin
depend
concentr
moreno
et
al
virushost
system
necessari
carri
experi
delimit
rang
inhibitor
mutagen
concentr
sequenti
treatment
advantag
translat
clinic
practic
interest
interplay
inhibitor
mutagen
agent
viral
popul
sequenti
versu
combin
treatment
figur
altern
antivir
design
use
inhibitor
mutagen
agent
model
studi
carri
fmdv
replic
cell
inhibitor
use
guanidin
hydrochlorid
gu
mutagen
ribavirin
r
four
type
serial
passag
p
indic
passag
number
top
bottom
passag
presenc
guanidin
alon
yellow
diamond
passag
presenc
ribavirin
r
alon
red
triangl
passag
presenc
mixtur
gu
r
denot
gu
r
red
star
passag
number
quot
first
passag
mixtur
gu
r
consid
equival
second
passag
presenc
singl
drug
final
first
passag
presenc
gu
follow
four
passag
presenc
r
blue
circl
b
c
viru
titer
viral
rna
level
cours
six
passag
presenc
mm
r
mm
gu
b
c
respect
passag
regimen
code
indic
box
note
highest
reduct
fmdv
progeni
product
achiev
use
sequenti
gur
protocol
blue
circl
infect
viral
rna
lost
earlier
highest
gu
concentr
test
e
highli
sensit
rtpcr
amplif
use
diagnost
viral
extinct
confirm
advantag
sequenti
guribavirin
treatment
symbol
figur
reproduc
peral
c
agudo
r
tejero
h
manrubia
sc
domingo
e
potenti
benefit
sequenti
inhibitormutagen
treatment
rna
viru
infect
plo
pathog
addit
experiment
detail
found
ad
complic
deriv
target
compartment
uneven
inhibitor
mutagen
concentr
differ
compart
steinmey
wilk
model
manrubia
j
iranzo
also
predict
therapi
base
use
either
two
mutagen
agent
two
inhibitor
combin
treatment
alway
prefer
sequenti
administr
studi
investig
consequ
use
two
mutagen
togeth
without
inhibitor
peral
et
al
dapp
et
al
avail
two
virusspecif
mutagen
agent
differ
mutat
prefer
advantag
target
differ
region
sequenc
space
relat
network
connect
discuss
chapter
although
result
mutat
pattern
may
difficult
interpret
dapp
et
al
also
mutagen
may
extinguish
viru
acquir
resist
anoth
mutagen
extinct
ribavirinresist
fmdv
mutant
fu
peral
et
al
accord
model
worst
option
administ
first
mutagen
inhibitor
unless
mutagen
achiev
extrem
reduct
viral
load
may
gener
expand
mutant
spectrum
inhibitorresist
mutant
may
select
iranzo
et
al
peral
et
al
lethal
mutagenesi
constitut
exampl
fundament
theoret
concept
initi
unrel
virolog
unfold
potenti
applic
form
antivir
design
transit
exemplifi
eigen
establish
basi
quasispeci
theori
eigen
wrote
comment
paper
viru
extinct
mutagen
nucleotid
year
later
eigen
imagin
grant
applic
work
quasispeci
aim
control
viral
infect
reader
probabl
object
immedi
noth
achiev
yet
lethal
mutagenesi
clinic
level
true
unless
ribavirin
clear
help
immun
system
clear
hcv
particip
mutagenesi
see
section
abl
talk
prospect
applic
suffici
make
point
relev
basic
research
prospect
address
box
list
advantag
limit
lethal
mutagenesi
treatment
compar
standard
nonmutagen
inhibitor
quantif
mutagenescap
mutant
frequenc
perform
deriv
box
n
e
r
c
n
b
e
w
e
e
n
n
h
b
r
n
u
g
e
n
c
n
u
c
l
e
e
h
c
n
f
f
e
c
h
e
e
f
fi
c
c
f
c
b
n
n
r
e
e
n
mutagen
increas
frequenc
inhibitorresist
mutant
inhibitor
prevent
replic
interf
mutant
contribut
lethal
defect
mutant
spectrum
suppress
inhibitorresist
mutant
affect
transcomplement
protein
mutagen
mutant
spectrum
suppress
highfit
genom
see
text
justif
refer
prospect
clinic
applic
lethal
mutagenesi
mutant
studi
section
requir
gradual
increas
mutagen
concentr
cours
select
passag
difficulti
isol
mutant
mutagentr
viral
popul
may
stem
suppress
environ
creat
mutagenesi
may
preclud
delay
domin
resist
mutant
possibl
sequenti
inhibitormutagen
treatment
section
clinic
relev
design
may
diminish
sever
side
effect
avoid
simultan
presenc
two
drug
treat
patient
shorter
treatment
durat
sequenti
treatment
also
possibl
natur
cellular
mechan
defens
genet
parasit
base
produc
excess
mutat
invad
chapter
section
apobec
apolipoprotein
b
mrna
edit
complex
adar
adenosin
deaminas
act
doublestrand
rna
discuss
exert
nucleic
acid
edit
function
use
cell
recruit
antivir
respons
harri
dudley
venkatesan
et
al
edit
part
replic
cycl
sever
virus
suggest
paramyxovirina
might
evolv
possess
genom
polyhexamer
length
known
rule
six
avoid
uncontrol
edit
error
catastroph
viru
kolakofski
et
al
addit
mutageniclik
activ
mimic
lethal
mutagenesi
one
term
rip
repeatinduc
point
mutat
oper
filament
fungi
mutat
genet
intrud
includ
transpos
element
galagan
selker
clutterbuck
braga
et
al
amselem
et
al
van
de
wouw
et
al
expert
regard
highli
posit
intend
medic
intervent
resembl
natur
process
box
v
n
g
e
n
l
n
f
n
v
r
l
r
e
e
n
b
e
n
l
e
h
l
u
g
e
n
e
advantag
possibl
high
barrier
resist
mechan
action
favor
suppress
possibl
resist
variant
mutagen
mutant
spectrum
within
infect
cell
lethal
mutagenesi
may
includ
sequenti
combin
design
class
antivir
agent
natur
mechan
resist
genet
parasit
includ
lethal
mutagenesislik
strategi
apobec
adar
rip
etc
mutagen
activ
agent
must
viru
specif
mutagen
cellular
nucleic
acid
possibl
offtarget
effect
still
poorli
understood
number
avail
antivir
mutagen
agent
restrict
addit
experi
anim
model
preclin
clinic
trial
need
prior
possibl
therapi
implement
resist
expert
panel
encourag
explor
unconvent
antivir
approach
scientif
commerci
reason
box
also
list
sever
limit
obviou
need
specif
mutagen
viral
cellular
nucleic
acid
lack
inform
offtarget
effect
necess
explor
treatment
efficaci
vivo
like
number
virusspecif
mutagen
agent
increas
come
decad
efficaci
vivo
properli
document
expert
panel
may
moder
attitud
toward
new
antivir
approach
discuss
licens
issu
peral
et
al
decis
suitabl
new
treatment
mainli
base
three
basic
paramet
cc
measur
toxic
ic
measur
inhibitori
potenti
therapeut
index
yield
ti
cc
ic
explain
section
chapter
addit
paramet
also
consid
spectrum
antivir
activ
regard
number
unrel
viral
pathogen
effect
inhibit
treatment
although
evid
still
lack
possibl
broadspectrum
sens
may
predict
capac
inhibit
broad
repertoir
quasispeci
swarm
appeal
broad
antivir
efficaci
depend
mechan
antivir
activ
preced
chapter
describ
two
class
broadspectrum
antivir
inhibitor
stimul
innat
immun
respons
notabl
inhibitor
pyrimidin
biosynthesi
mutagen
nucleotid
analog
notabl
ribavirin
favipiravir
relev
exampl
like
follow
addit
one
thu
would
interest
investig
joint
use
two
class
compound
stimul
immun
respons
lethal
mutagen
sequenti
combin
protocol
type
describ
section
drug
reposit
may
offer
addit
possibl
f
sobrino
colleagu
demonstr
valproic
acid
acid
vpa
display
broad
antivir
activ
mani
envelop
virus
martinaceb
et
al
vazquezcalvo
et
al
vpa
use
treat
epilepsi
bipolar
mania
among
disord
list
among
essenti
medicin
world
health
organ
despit
antivir
potenc
modest
inclus
part
combin
therapi
also
consid
view
broadspectrum
activ
tripl
broadspectrum
drug
combin
appear
attract
possibl
provid
antagonist
interact
avoid
side
effect
toler
long
way
go
lethal
mutagenesi
new
design
base
concept
list
box
appli
treatment
viral
diseas
howev
hope
experi
gain
mainli
also
errorpron
virus
favor
explor
regard
adapt
potenti
virus
major
challeng
confront
uncertain
whether
possibl
present
new
trend
antivir
strategi
satisfi
demand
new
paradigm
approach
infecti
diseas
emphas
open
paragraph
chapter
necessari
wait
innov
advanc
avail
possibl
common
trend
respond
quasispeci
challeng
fulfil
requir
express
repeatedli
book
viral
popul
control
deni
opportun
replic
replic
entail
explor
sequenc
space
condit
adapt
virus
hit
hard
soon
possibl
level
individu
infect
epidemiolog
level
extent
overview
conclud
remark
new
treatment
design
fulfil
requir
worth
pursu
probabl
combin
broadspectrum
antivir
agent
irrespect
natur
lethal
mutagen
stimul
immun
respons
mixtur
highli
neutral
antibodi
combin
among
best
option
present
avail
despit
gener
prefer
combin
treatment
mutagen
agent
enter
antivir
formul
possibl
sequenti
inhibitormutagen
treatment
consid
may
effect
correspond
combin
may
allevi
burden
side
effect
one
problem
current
treatment
given
challeng
exist
viral
diseas
emerg
viral
diseas
unavoid
come
done
minim
import
challeng
consequ
withdraw
focu
essenti
issu
antivir
design
must
plan
count
quasispeci
dynam
controversi
theoret
model
best
describ
extinct
virus
lethal
mutagenesi
use
clarifi
antivir
mechan
find
adjust
best
efficaci
controversi
present
evid
real
natur
dynam
quasispeci
applic
deep
sequenc
viral
popul
challeng
becom
dramat
evid
new
antivir
target
new
drug
mutagen
nonmutagen
studi
anim
model
hope
contribut
reach
goal
see
summari
box
need
develop
new
antivir
strategi
control
viral
pathogen
character
quasispeci
dynam
sever
new
design
implement
investig
aim
increas
barrier
resist
diminish
viral
fit
lethal
mutagenesi
consist
viru
extinct
excess
mutat
experiment
evid
suggest
lethal
mutagenesi
directli
relat
error
threshold
concept
quasispeci
theori
mutagenresist
viral
mutant
isol
studi
instrument
document
adapt
valu
confer
mutant
spectrum
adequ
complex
sever
molecular
mechan
viru
resist
mutagen
agent
one
modul
nucleotid
incorpor
select
counteract
mutat
bia
evok
mutagen
maintain
level
mutant
spectrum
divers
sequenti
inhibitormutagen
treatment
may
advantag
correspond
combin
depend
replic
paramet
viru
control
inhibitori
mutagen
intens
new
treatment
use
broadspectrum
mutagen
nonmutagen
drug
combin
offer
prospect
control
errorpron
virus
